GreenBe Pharma

Name

GreenBe Pharma

Legal name

GreenBE Pharma

Website

https://greenbepharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medicinal Cannabis APIs / Pharmaceutical Ingredients

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Medicinal Plant Farming (Botanical/Pharmaceutical Crops) (AFAGAGAE)

Keywords

• Medicinal cannabis cultivation
• EU-GMP cannabis flower
• Active pharmaceutical ingredients
• Cannabis API supply
• GACP certified production

Headquarters

HQ city

Elvas

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Cannabis Flower Sales (EU-GMP): Sale of high-quality dried cannabis flowers meeting EU-GMP certification requirements. Products include THC-dominant, CBD-dominant, and balanced chemotype varieties. Capacity of up to 50 kg per week of dried flowers or 2,500-4,000 kg per year depending on variety.
2. Active Pharmaceutical Ingredients (API): Supply of Active Pharmaceutical Ingredients for clinical trials, observational studies, and contractual research projects. Provided under EuGMP standards.
3. Research Services: Support services for research projects including design and implementation of research projects, laboratory personnel training and support, and chemotype supply for research purposes.
4. Extract and Purification: Second phase project to process flowers and obtain extracts and purifications of main cannabinoids using licensed technologies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

GreenBe Pharma cultivates medicinal cannabis in a GACP-certified greenhouse in Elvas, Portugal, and processes it in an adjacent EU-GMP facility to produce Active Pharmaceutical Ingredients (dried cannabis flowers with tailored THC, CBD, and CBDV chemotypes) supplied to pharmaceutical companies. The company also offers GMP cultivation and processing services, planned extraction/purification capabilities, and chemotype research services for clinical trials and contractual research projects.

Product overview

GreenBe Pharma is a medicinal cannabis company offering a vertically integrated portfolio of products and services for the pharmaceutical industry. The core offering includes five proprietary cannabis varieties (Variety A Type, Variety B Type, Variety C Type, Variety D Type, and Forbidden Dream) producing EU-GMP certified dried cannabis flowers as Active Pharmaceutical Ingredients. The company provides GACP-compliant cultivation services (10,000 m2 greenhouse facility) and GMP-compliant processing services (1,500 m2 processing unit) capable of producing 2,500-4,000 kg/year of dried flowers. Supporting services include extraction and purification capabilities, chemotype research services for clinical trials and contractual research, and distribution of Segra International tissue culture clones throughout Europe. The company develops 100% tailored solutions aligned to customer specifications for chemotype, terpene profile, and medical application requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• EU-GMP Cannabis Flower (Medicinal Cannabis API) High-quality dried cannabis flowers meeting EU-GMP certification requirements, supplied as Active Pharmaceutical Ingredients to pharmaceutical companies. Offered in tailored chemotypes including THC-dominant (Variety A Type, Forbidden Dream), Sativa-dominant THC with THCV (Variety B Type), balanced THC/CBD (Variety C Type), and CBD-dominant with CBDV (Variety D Type). Used by pharmaceutical manufacturers in medicines for chronic neuropathic pain, oncology support, Parkinson's, Multiple Sclerosis, and chemotherapy tolerance.
• GACP Cultivation Services Good Agricultural and Collection Practice (GACP) compliant cannabis cultivation in a 10,000 m² greenhouse comprising 19 cultivation rooms, 9 flowering rooms (5,000 m²), 9 vegetative phase rooms (2,500 m²), and a 1,000 m² mothers' room. Provides pharmaceutical clients a complete production chain from mother plants through cloning, rooting, vegetative growth, flowering, and harvesting.
• GMP Processing Services European Good Manufacturing Practice (EU-GMP) compliant processing in a 1,500 m² facility located 6 meters from the greenhouse shipping area. Capabilities include mechanical or manual trimming, drying in 4 rooms with independent environmental control, in-house quality control laboratory, bulk packaging (500 g primary batches), and irradiation services. Export capacity up to 50 kg/week or 2,500-4,000 kg/year of dried flowers.
• Extraction and Purification Services Second-phase service to process cannabis flowers and obtain extracts and purifications of main cannabinoids using licensed technologies. Intended to complement dried flower production with concentrated cannabinoid products for pharmaceutical customers.
• Chemotype Research Services Research services supplying GMP-compliant Active Pharmaceutical Ingredients (chemotypes) for biomedical research. Includes research project design and implementation support, laboratory personnel training, and chemotype supply for clinical trials, observational studies, and contractual research projects. Targeted at pharmaceutical companies and research institutions.
• Segra Tissue Culture Cannabis Clone Distribution European distribution of Segra International's proprietary tissue culture cannabis clones. Clones are DNA-fingerprinted, pathogen-tested, and genetically consistent, with uniform growth characteristics and stable cannabinoid and terpene profiles. Provides European licensed cultivators swift access to elite genetics, bypassing international import complexities.

Quantifiable outcome

• Production capacity of 50 kg/week or 2,500-4,000 kg/year of dried flowers
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Segra InternationalcoreTechnology or Integration · 20 January 2025Strategic partnership making GreenBe Pharma the central point of distribution for Segra's proprietary tissue culture cannabis clones throughout Europe. The collaboration enables European cultivators to efficiently access Segra's award-winning tissue culture cannabis clones through a localized European hub, reducing logistics and regulatory complexities associated with international imports. Segra provides DNA fingerprinting, pathogen-tested, genetically consistent clones; GreenBe Pharma provides GACP/GMP compliant facilities and local distribution.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Canopy Growth Corporation: Canopy Growth is a major global cannabis producer with EU-GMP medical cannabis operations in Europe producing dried flower APIs. Broad incumbent comparable to GreenBe's pharmaceutical-grade cannabis API offering, though at significantly larger scale.
• Aurora Cannabis: Aurora Cannabis operates EU-GMP certified medical cannabis production in Europe and produces dried flower and cannabinoid APIs for pharmaceutical distribution. Direct comparable as a multi-country EU-GMP cannabis API producer targeting pharmaceutical clients.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz Pharmaceuticals owns GW Pharmaceuticals, the originator of cannabinoid-based medicines (e.g., Sativex, Epidiolex) and a major buyer of cannabis APIs in Europe. Comparable as a pharmaceutical-grade cannabinoid-medicine counterpart and potential customer.
• Tilray Brands: Tilray is one of the largest global cannabis cultivators with EU-GMP certified medicinal cannabis production in Portugal and Germany, supplying pharmaceutical-grade flower and extracts across Europe. Directly comparable as a competitor in EU-GMP cannabis APIs targeting the same pharmaceutical customer segment.

Emerging players

• Flora Growth Corp: Flora Growth operates cannabis cultivation and processing facilities in Colombia with EU-GMP ambitions targeting European pharmaceutical supply. Comparable as an emerging multi-country cannabis cultivator pursuing the EU pharmaceutical API opportunity.

Direct peers

• Cantourage Group: Cantourage is a Berlin-based medical cannabis distribution and processing platform that imports EU-GMP cannabis flower and supplies German pharmacies. Directly comparable as a Europe-focused B2B medical cannabis supplier serving pharmaceutical channels.
• Segra International: Segra International is a Canadian cannabis ag-tech and tissue-culture genetics company whose clones are now distributed in Europe through GreenBe. Comparable as a cannabis-genetics IP holder and tissue-culture operator partnering with GreenBe for European distribution.
• Khiron Life Sciences: Khiron is a vertically integrated medical cannabis company focused on European and Latin American markets, producing EU-GMP flower and extracts for pharmaceutical distribution. Comparable in target markets, regulatory positioning, and product breadth.
• Clever Leaves: Clever Leaves is a vertically integrated medical cannabis cultivator with EU-GMP certification operating in Colombia and Portugal, supplying pharmaceutical-grade flower to European markets. Highly comparable in cultivation model, regulatory positioning, and customer segment.
• OrganiGram Holdings: OrganiGram is a Canadian licensed producer of medical and recreational cannabis with EU-GMP certification supplying European pharmaceutical markets with dried flower APIs. Closely comparable business model and product offering to GreenBe.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/greenbepharma
• LinkedInlinkedin.com/company/greenbe-pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GreenBe Pharma